Merck (NYSE: MRK) announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE